Verified reads
Research
Primary-source verification on public biotech assets — organized by pathway, ordered by where the deals are. Find the read nearest your asset; then point me at yours. Every claim is two clicks from the filing, the trial, or the paper that backs it.
Sometimes the data is worse than the deck. Sometimes it’s better than the market thinks. I tell you which.
The read
A Phase 3 hazard ratio of 0.16 sounds too good to be true. I read it against the published record — it holds.
Immunome (IMNM) · gamma-secretase inhibitor · desmoid tumor — read the report →
Browse by pathway — ordered by where the deals are
ADC
1 readantibody-drug conjugates — the hottest licensing space of 2025
Immunology & inflammation
1 readthe fastest-growing share of biopharma dealmaking
RNA & oligonucleotide
2 readsthree Novartis mega-deals in twelve months
- Moderna, Inc.MRNA
modRNA platform · seasonal respiratory + oncology
Four prophylactic mRNA approvals shipped. mRNA-1010 PDUFA August 5; INTerpath-001 melanoma readout next. The strain-B liability that felled Sanofi and Pfizer/BioNTech still applies.
- Wave Life SciencesWVE
GalNAc-conjugated AIMer · alpha-1 antitrypsin deficiency
GalNAc cleared 11 µM where one LNP didn’t. Beam’s LNP cleared it harder.
RAS / MAPK & targeted solid tumors
5 readsthe deepest cluster — where most of the readouts land
- Immuneering CorporationIMRX
deep-cyclic MEK inhibitor (atebimetinib / IMM-1-104) · 1L metastatic pancreatic cancer
Atebimetinib + modified gem/nab-paclitaxel reported a 17.3-month median overall survival in first-line metastatic PDAC (N=55), against a MEK-in-PDAC record of two peer-reviewed failures. The full Phase 2a data present at ASCO abstract 4013 on June 1; it sets the MEK + chemotherapy control bar the RAS cluster is read against.
- Relay Therapeutics, Inc.RLAY
FGFR2 + mutant-selective PI3Kα · solid tumors
Mechanism validated by prior art. The 490-patient ReFocus finished in September. The data still has not appeared.
- Immunome, Inc.IMNM
gamma-secretase inhibitor · desmoid tumor
Phase 3 hazard ratio 0.16. NDA filed April 29. ASCO oral on May 30 fills in subgroup detail.
- IDEAYA Biosciences, Inc.IDYA
PKC inhibitor + c-MET · HLA*A2(-) metastatic uveal melanoma
OptimUM-02 hit. HR 0.42, mPFS 6.9 vs 3.1 mo. NDA H2 2026. ASCO LBA9503 fills in the rest June 1.
- Compass TherapeuticsCMPX
DLL4×VEGF-A bispecific · biliary tract cancer
Primary hit. Secondary hit. OS missed because 54% of placebo crossed over.
AI-designed biologics
1 readwhite-hot venture; the diligence is on the asset, not the platform
Gene therapy
1 readrecovering and volatile — asset outcomes are binary
Rare & metabolic
1 readniche endocrine and rare-disease assets
Congress hubs
See every read on the readout calendar — by date →
How to read these reports
Three terms recur — defined once, so a flag reads as data, not an accusation. An overstatement is a published claim that runs ahead of its own source: common, and usually optimism rather than fraud. A missing-data flag marks something the pitch leans on but that I cannot find in any primary record — a filing, a trial, a label. A PRR (proportional reporting ratio) measures how often a side effect attaches to one drug versus all others; a high value flags an adverse-event signal worth a closer look. None is a verdict on its own. Treat each as a single data point, and pursue the ones that bear on your decision.
Calibration
What a readout is worth: seven reads written down before ASCO and EHA 2026, scored in the open — with the misses shown.
A scorecard you cannot lose on is not a scorecard — read the full card →
Perspectives
The thinking behind the reads — long-form arguments from the published record.
Read the essays →